1-20 of 35
Martine Escoffre Barbe, MD
Close
Sort by
Journal Articles

Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

Laurent Garderet, MD PhD, Hafida Ouldjeriouat, Mohamed-Amine Bekadja, Elisabeth Daguenet, PhD, Laure Vincent, Damien roos Weil, Marguerite Vignon, MD, Mohamad Mohty, MD PhD, Julie Abraham, MD, Martine Escoffre-Barbe, MD, Bruno Lioure, MD, Redhouane Ahmed Nacer, MD PhD, Denis Caillot, Clara Mariette, MD, Lionel Karlin, MD, Pierre Morel, MD, Lila Gilis, MD, Emanuelle Leray, Anaise Blouet, MD, Nicole Raus, Data Manager, Marie Robin, MD PhD, jean Jacques Boffa, Pierre Ronco, Marie Thérèse Rubio, MD PhD, Jérôme Cornillon, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-140713
Published: 2020
Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 28.
https://doi.org/10.1182/blood-2019-123719
Published: 2019
Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 30.
https://doi.org/10.1182/blood-2019-124408
Published: 2019
Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Franck E Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnès Guerci-Bresler, MD PhD, Aude Charbonnier, MD PhD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD PhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, MD PhD, Denis Guyotat, MD PhD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Eric Deconinck, MD PhD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Alexandre Deloire, CRA, Stephane Morisset, BioStat, Madeleine Etienne, CRA, Delphine Rea, MD, Stephanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 494.
https://doi.org/10.1182/blood-2019-123674
Published: 2019
Journal Articles

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Jean-Michel Cayuela, Francois Lay, MD, Yves Chalandon, Philippe Rousselot, MD PhD, Xavier Thomas, MD PhD, Violaine Havelange, MD, Francoise Huguet, MD, Patrice Chevallier, MD, Anne Thiebaut-Bertrand, Sylvain Chantepie, MD, Nicolas Boissel, MD PhD, Norbert Vey, MD PhD, Martine Escoffre-Barbe, MD, Franciane Paul, Celine Berthon, MD PhD, Isabelle Plantier, MD, Mathilde Hunault, MD PhD, Carlos Graux, Veronique Lheritier, Sylvie Chevret, MD PhD, Hervé Dombret
Journal: Blood
Blood (2019) 134 (Supplement_1): 1295.
https://doi.org/10.1182/blood-2019-124029
Published: 2019
Journal Articles

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Oliver G. Ottmann, MD, Heike Pfeifer, MD, Jean-Michel Cayuela, PhD, Karsten Spiekermann, MD, Wolfram Jung, MD, Joachim Beck, Emmanuel Raffoux, MD, Pascal Turlure, MD, Chantal Himberlin, Francoise Huguet, MD, Andreas Viardot, MD, Knut Wendelin, MD, Albrecht Reichle, MD, Sébastien Maury, MD PhD, Laurence Sanhes, MD, Francoise Isnard, PhD, Jean-Yves Cahn, MD, Stephane Lepretre, Patrice Chevallier, MD, Martine Escoffre-Barbe, MD, Josep-Maria Ribera, MD PhD, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Hervé Dombret, Philippe Rousselot, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 31.
https://doi.org/10.1182/blood-2018-99-114552
Published: 2018
Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Marie Balsat, MD, Vincent Alcazer, MD, Gabriel Etienne, MD PhD, Gaelle Fossard, MD, Francoise Huguet, MD, Marc G. Berger, MD PhD, Emilie Cayssials, MD, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Hyacinthe Johnson-Ansah, MD, Viviane Dubruille, MD, Laurence Legros, MD PhD, Lydia Roy, MD, Alain Jacques Delmer, MD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Fabrice Larosa, Stephane Courby, MD, Shanti Ame, MD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD, Franck Emmanuel Nicolini, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 48.
https://doi.org/10.1182/blood-2018-99-113058
Published: 2018
Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MDPhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD PhD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, MD, Martine Gardembas, MD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Verane Schwiertz, PharmD, Stephane Morisset, Stat, Madeleine Etienne, CRA, Delphine Rea, MD PhD, Stephanie Dulucq, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 899.
https://doi.org/10.1182/blood.V130.Suppl_1.899.899
Published: 2017
Journal Articles

A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

Laurent Garderet, MD PhD, Frederique Kuhnowski, MD, jean Yves Mary, MD, Murielle Roussel, Martine Escoffre-Barbe, MD, Ingrid Lafon, MD, Thierry Facon, MD, Lionel Karlin, MD, Aurore Perrot, MD, Philippe Moreau, MDPhD, Gerald Marit, MD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Carine Chaleteix, MD, Mourad Tiab, Carla Araujo, MD, Pascal Lenain, MD, Margaret Macro, MD, Eric Voog, MD, Lofti Benboubker, MD, Olivier Allangba, MD, Eric Jourdan, MD, Mohamad Mohty, MD PhD, Herve Avet Loiseau, MD PhD, Claire Mathiot, MD, Michel Attal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 837.
https://doi.org/10.1182/blood.V130.Suppl_1.837.837
Published: 2017
Journal Articles

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Murielle Roussel, Benjamin Hebraud, MD, Valerie Lauwers-Cances, MD, Margaret Macro, MD, Xavier Leleu, MD PhD, Cyrille Hulin, MD, Lionel Karlin, MD, Bruno Royer, MD, Aurore Perrot, MD, Philippe Moreau, MDPhD, Denis Caillot, MD, Sophie Rigaudeau, MD, Mamoun Dib, MD, Emmanuelle Nicolas-Virelizier, MD, Martine Escoffre-Barbe, MD, Karim Belhadj, MD, Brigitte Pegourie, MD, Anne-Marie Stoppa, MD, Carla Araujo, MD, Chantal Doyen, MD, Jean Fontan, MD, Brigitte Kolb, MD, Laurent Garderet, MD PhD, Sabine Brechignac, MD, Jean Valere Malfuson, MD, Veronique Dorvaux, MD, Pascal Lenain, MD, Omar Benbrahim, MD, Arnaud Jaccard, Cecile Borel, MD, Herve Avet Loiseau, MD PhD, Michel Attal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 398.
https://doi.org/10.1182/blood.V130.Suppl_1.398.398
Published: 2017
Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 313.
https://doi.org/10.1182/blood.V130.Suppl_1.313.313
Published: 2017
Journal Articles

The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study

Françoise Huguet, MD, Thibaut Leguay, Xavier Thomas, MD PhD, Nicolas Boissel, MD PhD, Martine Escoffre-Barbe, MD, Patrice Chevallier, MD PhD, Mathilde Hunault, MD PhD, Norbert Vey, MD, Caroline Bonmati, MD, Stéphane Leprêtre, MD, Jean-Pierre Marolleau, MD PhD, Thomas Pabst, MD PhD, Philippe Rousselot, MD PhD, Agnès Buzyn, MD PhD, Jean-Yves Cahn, MD, Véronique Lhéritier, Marie C Béné, PharmD, PhD, Vahid Asnafi, MD PhD, Eric Delabesse, PharmD, PhD, Elizabeth Macintyre, MD PhD, Yves Chalandon, MD, Norbert Ifrah, Hervé Dombret, MD
Journal: Blood
Blood (2016) 128 (22): 762.
https://doi.org/10.1182/blood.V128.22.762.762
Published: 2016
Journal Articles

Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)

Oliver G. Ottmann, MD, Heike Pfeifer, MD, Jean-Michel Cayuela, Karsten Spiekermann, MD, Joachim Beck, MD, Wolfram E Jung, MD, Andreas Viardot, Schäfer-Eckart Kerstin, MD, Albrecht Reichle, Sébastien Maury, MD, Norbert Schmitz, MD, Daniela Heidenreich, Jens Panse, MD, Christian Junghanß, MD, Emmanuel Raffoux, MD, Felipe Suarez, MD PhD, Gäelle Guillerm, Magda Alexis, Severine Lissandre, MD, Françoise Huguet, MD, Françoise Isnard, MD, Stephane Lepretre, MD, Martine Escoffre-Barbe, MD, Josep-Maria Ribera, MD PhD, Nicola Goekbuget, MD, Herve Dombret, MD, Dieter Hoelzer, MD, Philippe Rousselot, MD
Journal: Blood
Blood (2014) 124 (21): 798.
https://doi.org/10.1182/blood.V124.21.798.798
Published: 2014
Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Patrice Chevallier, MD PhD, Thomas Eugene, MD, Nelly Robillard, Françoise Isnard, MD, Franck E Nicolini, MD PhD, Martine Escoffre-Barbe, MD, Françoise Huguet, Mathilde Hunault, Antoine Marcais, MD, Thierry Guillaume, Jacques Delaunay, MD, Pierre Peterlin, MD, Xavier Thomas, MD PhD, Norbert Ifrah, Simona Lapusan, Caroline bodet-Milin, MD, Alain faivre Chauvet, Claire Le Houerou, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Françoise Kraeber-Bodere, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3708.
https://doi.org/10.1182/blood.V124.21.3708.3708
Published: 2014
Journal Articles

Hevylite® to Monitor Response to Therapy in Multiple Myeloma

Guillemette Fouquet, MD, Susanna Schraen, MD, Jean-Luc Faucompré, MD, Lionel Karlin, Margaret Macro, MD, Cyrille Hulin, MD, Brigitte Onraed, MD, Laurent Garderet, MD, Murielle Roussel, MD, Bertrand Arnulf, Brigitte Pegourie, MD, Brigitte Kolb, Anne-Marie Stoppa, MD, Sabine Brechignac, MD, Mauricette Michallet, MD PhD, Gerald Marit, Claire Mathiot, MD, Anne Banos, MD, Mourad Tiab, MD, Mamoun Dib, Jean-Gabriel Fuzibet, MD, Marie-Odile Petillon, MD, Philippe Rodon, MD, Marc Wetterwald, MD PhD, Bruno Royer, MD, Laurence Legros, MD, Lofti Benboubker, MD, Olivier Decaux, Denis Caillot, MD, Martine Escoffre-Barbe, MD, Jean-Paul Fermand, MD, Philippe Moreau, MD, Michel Attal, Hervé Avet-Loiseau, Thierry Facon, MD, Xavier Leleu, MD
Journal: Blood
Blood (2014) 124 (21): 2021.
https://doi.org/10.1182/blood.V124.21.2021.2021
Published: 2014
Journal Articles

Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients

Gaelle Fossard, MD, Emilie Blond, Pharm.D, Stephane Giraudier, MD PhD, Stephane Morisset, Stat., Jeremy Ruby, CRA student, Martine Escoffre-Barbe, MD, Hélène Labussière-Wallet, MD, Mael Heiblig, MD, Madeleine Etienne, CRA, Jocelyne Drai, Pharm.D, Mohamad Sobh, Pharm.M., Mauricette Michallet, MD PhD, Isabelle Redonnet-vernhet, MD PhD, Jean-christophe Lega, MD PhD, Gabriel Etienne, MD PhD, Franck E. Nicolini, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3136.
https://doi.org/10.1182/blood.V124.21.3136.3136
Published: 2014
Journal Articles

Characteristics and Outcomes of Unselected Adolescents and Young Adults Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Stéphanie Bernardin, Franck E. Nicolini, MD PhD, Delphine Rea, MD PhD, Mael Haiblig, MD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, P Cony-Makhoul, MD, Martine Escoffre-Barbe, MD, Stephane Giraudier, Agnes Guerci-Bresler, MD PhD, Valérie Coiteux, MD, Marc G Berger, MD PhD Professor, Lydia Roy, MD, Anne Corby, MD, Pierre-Simon Rohrlich, MDPhD, Françoise Huguet, MD, Laurence Legros, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1803.
https://doi.org/10.1182/blood.V124.21.1803.1803
Published: 2014
Journal Articles

Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferonα2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la leucemie myéloïde chronique)

Francois Guilhot, Francoise Rigal-Huguet, MD, Joelle Guilhot, PhD, Agnès Guerci-Bresler, MD, Franck E. Nicolini, MD PhD, Frédéric Maloisel, Delphine Rea, MD PhD, Valerie Coiteux, MD, Martine Gardembas, MD, Anne Vekhoff, MD, Eric Jourdan, MD PhD, Laurence Legros, MD PhD, Martine Escoffre-Barbe, MD, Philippe Rousselot, MD, Claude Preudhomme, MD PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1793.
https://doi.org/10.1182/blood.V124.21.1793.1793
Published: 2014
Journal Articles

Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study

Franck E. Nicolini, MD PhD, Nicolas Vantard, Pharm.D, Stephane Giraudier, MD PhD, Mael Heiblig, MD, Hyacinthe Johnson-Ansah, MD, Lydia Roy, MD, Claude-Eric Bulabois, MD, Denis Caillot, MD, Martine Escoffre-Barbe, MD, Eric Jourdan, MD PhD, Pascale Cony-Makhoul, MD, Agnes Guerci-Bresler, MD PhD, Laurence Legros, MD PhD, Laurent Sutton, MD, Martine Gardembas, MD, Emmanuel Gyan, MD PhD, Annelore Le Maux, Stat., Carine Guinard-Azadian, MD, Hesham Mohamed, MD, Mohamad Sobh, Pharm.M., Helene Labussiere-Wallet, MD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1321.
https://doi.org/10.1182/blood.V124.21.1321.1321
Published: 2014
Journal Articles

Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide

Denis Caillot, MD, Muriel Newingerm, MD, Margaret Macro, MD, Brigitte Pegourie, MD, Lionel Karlin, MD, Francesca Gay, MD, Claire Bories, MD, Laurence Legros, MD PhD, Laurent Garderet, MD, Souhila Ikhlef, MD, Martine Escoffre-Barbe, MD, Bruno Royer, MD, Laurent Voillat, MD, Cyrille Hulin, MD, Anne Banos, MD, Eric G. Voog, MD, Anne-Marie Stoppa, MD, Lotfi Benboubker, MD PhD, Eva De Jongh, Sonja Zweegman, MDPhD, Niels Abildgaard, MD, Katell Le Dû, Artur J. Jurczyszyn, MD PhD, Philippe Moreau, MD, Thierry Facon, MD, Evangelos Terpos, Xavier Leleu, MD, Catherine Vieira Dos Santos, Helene Demarquette, MD
Journal: Blood
Blood (2014) 124 (21): 5702.
https://doi.org/10.1182/blood.V124.21.5702.5702
Published: 2014